02/09/2020 (Agence Europe) – The European Medicines Agency (EMA) is currently examining the possibility of authorising the use of Dexamethasone Taw to treat adult inpatients with Covid-19, the Agency announced in a press release on Wednesday 2 September. Drugs bases on Dexamethasone Taw have been approved for several decades to treat various infections due to their anti-inflammatory properties. The British Recovery trial had highlighted the good results of this drug in July 2020. The application submitted by the manufacturer Taw Pharma will be evaluated by the Agency’s Committee for Medicinal Products for Human Use (CHMP) on an accelerated timetable. The EMA will then make a recommendation to the Commission, which will have to accept or refuse the application. At this stage, only one drug has passed this stage: Remesivir (see EUROPE 12520/19). (SPj)